Showing 473 results
-
Press release /New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
-
Press release /CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
-
Press release /Unique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data…
-
Press release /Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early…
-
Press release /Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug…
-
Press release /Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with…
-
Press release /Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
-
Press release /Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
-
Press release /RATIONALE 301 trial met its objective at final analysis, demonstrating non-inferior overall survival (OS) for tislelizumab (median OS: 15.9 months) versus sorafenib (median OS: 14.1 months) in…
-
Press release /Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…